ADMS Adamas Pharmaceuticals Inc.

4.12
-0.01  -0%
Previous Close 4.13
Open 4.18
52 Week Low 1.9
52 Week High 7.45
Market Cap $116,521,181
Shares 28,281,840
Float 23,509,324
Enterprise Value $147,740,633
Volume 246,688
Av. Daily Volume 593,272
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
GOCOVRI (ADS-5102)
Levodopa-Induced Dyskinesia + Parkinson's disease patients receiving levodopa and experiencing OFF episodes
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
GOCOVRI (amantadine)
Multiple sclerosis (MS)
Phase 3
Phase 3
Phase 3 data met primary endpoint at one of two doses. Secondary endpoint in walking impairment not met. Second trial will not be initiated as a result of data - December 17, 2019. Findings were confirmed June 17, 2020.
GOCOVRI (amantadine)
Dyskinesia patients with Parkinson's disease
Phase 3
Phase 3
Phase 3 open-label data released April 19, 2018.
Namzaric
Moderate to severe dementia of the Alzheimer's type.
Approved
Approved
Approved December, 24 2014.

Latest News

  1. EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2020 Virtual Congress, September 12-16, 2020.

    "These presentations provide further evidence that GOCOVRI may reduce OFF time for people with Parkinson's, with prolonged effects for at least two years," said Jean Hubble MD, Vice President, Medical Affairs at Adamas. "Both dyskinesia…

    EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy at the Movement Disorder Society (MDS) 2020 Virtual Congress, September 12-16, 2020.

    "These presentations provide further evidence that GOCOVRI may reduce OFF time for people with Parkinson's, with prolonged effects for at least two years," said Jean Hubble MD, Vice President, Medical Affairs at Adamas. "Both dyskinesia and OFF disrupt daily activities for people with PD and treating dyskinesia should not come at the expense of increased OFF, or vice versa. For patients who seek good ON time with long-term reductions in dyskinesia and OFF, providers can consider GOCOVRI as a treatment option shown to provide substantial and sustained benefits."

    The following posters will be available in the MDS 2020 Virtual Poster Hall beginning September 11, 2020:

    Poster #896: Among Parkinson's disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials

    Lead Author: Robert A. Hauser, MD, MBA, USF Parkinson's Disease and Movement Disorders Center, Parkinson Foundation Center of Excellence.

    Poster #955: Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson's disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial

    Lead Author: Caroline M. Tanner, MD, PhD, University of California San Francisco.

    About Parkinson's Disease, Dyskinesia, and OFF

    Parkinson's Disease (PD) is a progressive, neurodegenerative disorder caused by the gradual loss of brain cells that produce the neurotransmitter dopamine and affects approximately one million people in the United States. Dopamine decline in the brain results in a wide range of motor (movement-related) and non-motor symptoms. As the disease progresses, people are likely to experience unpredictable stiffness, rigidity, and tremors, referred to as OFF time. The primary treatment for PD is with levodopa; however, over time levodopa may lead to involuntary, uncontrolled movements known as dyskinesia. The abrupt and unpredictable transitions between episodes of dyskinesia, normal movement, and OFF time lead to considerable impact on patients' lives.

    About GOCOVRI®

    GOCOVRI® (amantadine) extended-release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also the only medicine clinically proven to reduce both dyskinesia and OFF. Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls, and orthostatic hypotension. For more information about GOCOVRI, please visit www.GOCOVRI.com.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS

    GOCOVRI® is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2

    WARNINGS AND PRECAUTIONS

    Falling Asleep During Activities of Daily Living and Somnolence:  Patients treated with Parkinson's disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

    Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression. 

    Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

    Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

    Withdrawal-Emergent Hyperpyrexia and Confusion:  Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson's disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech.   Avoid sudden discontinuation of GOCOVRI.

    Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

    ADVERSE REACTIONS

    The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and, orthostatic hypotension.

    Please see full Prescribing Information for additional important safety information at https://www.gocovri.com/assets/pdfs/Gocovri_Prescribing_Information.pdf.

    About Adamas

    At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

    Forward-looking statements

    Statements contained in this press release regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas' expectations of its full year 2020 expenses. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas' research, clinical, development and commercial activities relating to GOCOVRI and ADS-5102, and the regulatory and competitive environment and Adamas' business in general, see Adamas' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2020, particularly under the caption "Risk Factors." In addition, the impact that the current COVID-19 pandemic is having and will have on demand for GOCOVRI, and the unknown duration and severity of the COVID-19 pandemic, add additional risk and uncertainty to these forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

    Contact:

    Media:

    Sarah Mathieson

    Vice President of Corporate Communications

    510-450-3528





     
    Investors:

    Peter Vozzo

    Managing Director, Westwicke

    443-213-0505





     

    Primary Logo

    View Full Article Hide Full Article
  2. EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company's Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15th at 12:30 pm Eastern Time (9:30 am Pacific). 

    The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentation.

    About Adamas Pharmaceuticals,

    EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company's Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15th at 12:30 pm Eastern Time (9:30 am Pacific). 

    The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentation.

    About Adamas Pharmaceuticals, Inc.

    At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.

    Contact:

    Investors:

    Peter Vozzo

    Managing Director, Westwicke

    443-213-0505

    Media:

    Sarah Mathieson

    Vice President of Corporate Communications

    510-450-3528

    Primary Logo

    View Full Article Hide Full Article
  3. EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Anna Richo, J.D., General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, Inc., to its Board of Directors. She will also serve on the Audit Committee. Ms. Richo brings over 30 years of leadership experience managing legal and compliance functions within the biotechnology and pharmaceutical industry, including UCB, Amgen, and Baxter Healthcare as well as prior public-company Board, Audit, and Finance Committee experience at Cytyc Corporation.

    "We are…

    EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Anna Richo, J.D., General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, Inc., to its Board of Directors. She will also serve on the Audit Committee. Ms. Richo brings over 30 years of leadership experience managing legal and compliance functions within the biotechnology and pharmaceutical industry, including UCB, Amgen, and Baxter Healthcare as well as prior public-company Board, Audit, and Finance Committee experience at Cytyc Corporation.

    "We are delighted to welcome Anna to our board during this exciting time of growth for us as a commercial organization," said David L. Mahoney, Chairman, Adamas. "Anna brings extensive and relevant operational expertise, and we look forward to her contributions as we continue to advance and evolve Adamas," added Neil F. McFarlane, CEO.

    "I am excited to work with the Adamas Board of Directors and management team given the company's strong patient focus," said Ms. Richo. "I look forward to partnering with the team to help the company reach its long-term goals and deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society."

    Having joined Cargill in 2019, Ms. Richo's successful career path includes leadership roles in biotechnology and pharmaceutical companies as general counsel and leading compliance, intellectual property, and corporate litigation. Ms. Richo has previously been recognized as one of the 'Top 15 Women in Pharma'.  She holds a bachelor's degree in industrial and labor relations from Cornell University and a J.D. degree from DePaul University, College of Law. She is a member of the Board of Trustees for DePaul University.

    About Adamas

    At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

    Contact:

    Media:

    Sarah Mathieson

    Vice President of Corporate Communications

    510-450-3528



    Investors:

    Peter Vozzo

    Managing Director, Westwicke

    443-213-0505

      

    Primary Logo

    View Full Article Hide Full Article
  4. Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019

    Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019

    EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2020, and recent corporate highlights. 

    "Adamas delivered a strong performance this quarter, reflecting the successful execution of our growth strategy as well as our ability to rapidly adapt to the challenges posed by the ongoing pandemic," said Neil F. McFarlane…

    Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019

    Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019

    EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended June 30, 2020, and recent corporate highlights. 

    "Adamas delivered a strong performance this quarter, reflecting the successful execution of our growth strategy as well as our ability to rapidly adapt to the challenges posed by the ongoing pandemic," said Neil F. McFarlane, Chief Executive Officer. "Additionally, we achieved a key milestone during the quarter with the FDA acceptance for review of our sNDA for GOCOVRI as a treatment for OFF episodes in Parkinson's disease patients receiving levodopa-based therapy. As we continue to respond to an uncertain environment, our focus remains on serving the patient community."

    Recent highlights

    • GOCOVRI product sales were $18.0 million in the second quarter of 2020, an increase of 41% as compared to $12.7 million in the second quarter of 2019.
    • Total paid prescriptions (TRx) of GOCOVRI were approximately 8,150 in the second quarter of 2020, a 32% increase over approximately 6,160 TRx in the second quarter of 2019 and an increase of 13% over approximately 7,210 TRx in the first quarter of 2020. Strong patient persistence of 45%-50% at 12 months continued for GOCOVRI in the second quarter of 2020.
    • New paid prescriptions (NRx) of GOCOVRI were approximately 370 in the second quarter of 2020 compared to NRx of approximately 500 in the first quarter of 2020, reflecting a decline in patient visits to clinics due to the pandemic during the second quarter of 2020.
    • The Company began earning royalty revenue on net sales of NAMZARIC® beginning May 18, 2020, recognizing $0.8 million in the second quarter of 2020. Royalties will be earned quarterly through 2024.
    • Supplemental New Drug Application for GOCOVRI as a treatment for OFF episodes in Parkinson's disease (PD) patients receiving levodopa-based therapy was accepted for review by the U.S. Food and Drug Administration. The anticipated Prescription Drug User Fee Act action date is February 1, 2021.
    • The United States Patent and Trademark Office issued a new patent for GOCOVRI that covers a method of reducing OFF time and increasing good ON time in people with PD being treated with levodopa.

    Financial results

    Revenue

    Total revenue was $18.8 million for the second quarter of 2020, consisting of GOCOVRI product sales of $18.0 million and royalty revenue earned on net sales of NAMZARIC of $0.8 million. GOCOVRI product sales were up 41% compared to $12.7 million in the same period in 2019.

    Research and Development (R&D) expenses

    R&D expenses for the second quarter of 2020 were $2.6 million, compared to $8.6 million for the same period in the prior year. R&D expenses in the second quarter of 2020 substantially relate to ongoing clinical development activities, including an open-label study which will conclude by the end of 2020 and completing the assessment of the ADS-5102 program. The decrease in R&D expenses from the prior year quarter was primarily due to the completion of the Phase 3 INROADS trial for the treatment of multiple sclerosis patients with walking impairment at the end of 2019.

    Selling, General and Administrative (SG&A) expenses

    SG&A expenses for the second quarter of 2020 were $23.2 million, compared to $25.2 million for the same period in the prior year.  SG&A expenses in the second quarter of 2020 were primarily attributable to sales force costs and external spend dedicated to GOCOVRI commercialization and the related administrative support. The decrease from prior year quarter was primarily attributable to a combination of cost management activities as well as a reduced cost structure while executing in a virtual environment.  

    Net loss

    Net loss was $10.6 million, or $0.37 per share, basic and diluted, for the second quarter of 2020, compared to a net loss of $24.9 million, or $0.90 per share, basic and diluted, for the second quarter of 2019. Net loss for the second quarters of 2020 and 2019 included $1.7 million and $2.9 million, respectively, in non-cash stock-based compensation expense.

    Cash and investments

    As of June 30, 2020, the Company had $103.4 million of cash, cash equivalents and available-for-sale securities, compared to $132.6 million at December 31, 2019.

    Full year 2020 expense guidance

    The Company is updating its full year 2020 guidance for R&D and stock-based compensation expenses as set forth below:

      Current (as of August 6, 2020) Previous (as of May 7, 2020)
    R&D expenses1 $8 million -- $12 million $10 million -- $15 million
    SG&A expenses2 $105 million -- $115 million $105 million -- $115 million
    Total operating expenses3 $113 million -- $127 million $115 million -- $130 million
         

    1Includes stock-based compensation expense of $1 million.

    2Includes stock-based compensation expense of $7 million.

    3Includes stock-based compensation expense of $8 million. 

    Investor conference call and webcast

    Adamas will host a conference call and webcast today, August 6, 2020, at 4:30 p.m. ET (1:30 p.m. PT). The conference call may be accessed by dialing (833) 350-1318 (U.S./Canada) or (236) 738-2277 (international) using the ID 4795503. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for replay until November 5, 2020.

    About GOCOVRI®

    GOCOVRI® (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also the only medicine clinically proven to reduce both dyskinesia and OFF.

    Taken once daily at bedtime, GOCOVRI provides an initial lag and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day. Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.

    For more information about GOCOVRI, please visit www.GOCOVRI.com.

    NAMZARIC®

    For more information, please visit www.NAMZARIC.com.

    About Adamas

    At Adamas our vision is clear - to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

    Forward-looking statements

    Statements contained in this press release regarding matters that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding Adamas' expectations of its full year 2020 expenses. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas' research, clinical, development and commercial activities relating to GOCOVRI and ADS-5102, and the regulatory and competitive environment and Adamas' business in general, see Adamas' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2020, particularly under the caption "Risk Factors." In addition, the impact that the current COVID-19 pandemic is having and will have on demand for GOCOVRI, and the unknown duration and severity of the COVID-19 pandemic, add additional risk and uncertainty to these forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

    Contact:

    Investors:Media:
    Peter VozzoSarah Mathieson
    WestwickeVice President of Corporate Communications
    443-213-0505510-450-3528
      

    — Financial Tables Attached —

    Adamas Pharmaceuticals, Inc.

    Unaudited Condensed Consolidated Statements of Operations

    (in thousands, except per share data)

     Three Months Ended

     June 30,
     Six Months Ended

     June 30,
     2020 2019 2020 2019
    Revenues:       
    Product sales$17,954  $12,691  $32,435  $24,356 
    Royalty revenue840    840   
    Total revenues18,794  12,691  33,275  24,356 
    Costs and operating expenses:       
    Cost of product sales381  685  953  1,098 
    Research and development2,550  8,598  5,015  18,812 
    Selling, general and administrative, net23,177  25,216  47,729  52,904 
    Total costs and operating expenses26,108  34,499  53,697  72,814 
    Loss from operations(7,314) (21,808) (20,422) (48,458)
    Interest and other income, net215  734  299  1,457 
    Interest expense(3,467) (3,797) (7,091) (7,528)
    Net loss$(10,566) $(24,871) $(27,214) $(54,529)
    Net loss per share, basic and diluted$(0.37) $(0.90) $(0.97) $(1.98)
    Weighted average shares used in computing net loss per share, basic and diluted28,194  27,579  28,112  27,516 
                

    Adamas Pharmaceuticals, Inc.

    Unaudited Consolidated Balance Sheet Data

    (in thousands)

     June 30,

    2020
     December 31,

    2019
    Cash, cash equivalents, and available-for-sale securities$103,414  $132,607 
    Total assets133,065  162,158 
    Total current liabilities21,215  26,948 
    Long-term debt126,300  125,674 
    Total liabilities157,474  163,051 
    Total stockholders' deficit(24,409) (893)
          

    Primary Logo

    View Full Article Hide Full Article
  5. EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

    Investor Conference Call and Webcast
    The conference call can be accessed by dialing (833) 350-1318 for participants in the U.S. or Canada and (236) 738-2277 for international callers. All callers must provide the following Conference ID: 4795503.    The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations

    EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

    Investor Conference Call and Webcast

    The conference call can be accessed by dialing (833) 350-1318 for participants in the U.S. or Canada and (236) 738-2277 for international callers. All callers must provide the following Conference ID: 4795503.    The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay until November 5, 2020.

    About Adamas Pharmaceuticals, Inc.

    At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com. 

    Contact

    Investors:

    Peter Vozzo

    Managing Director, Westwicke

    443-213-0505

    Media:

    Sarah Mathieson

    Vice President, Corporate Communications

    510-450-3528

    Primary Logo

    View Full Article Hide Full Article
View All Adamas Pharmaceuticals Inc. News